Two biotechs—Latigo Biotherapeutics and Blossomhill Therapeutics—capitalized on a stronger IPO tape, each pushing past expectations in recent debuts. Latigo’s non-opioid, Nav1.8-focused pipeline and Blossomhill’s macrocyclic oncology strategy attracted investor demand amid a market looking for differentiated mechanisms. Latigo priced its offering at the high end of its range, raising about $345.6 million to advance its Nav1.8 pain program, while Blossomhill priced a $150 million IPO to fund next-generation macrocyclic inhibitors, including programs aimed at EGFR-mutant non-small-cell lung cancer. The take is practical for the sector: investors are still funding platforms and mechanism-led clinical strategies, particularly when the pipeline is framed around a clear late-stage path and credible competitive differentiation.